Literature DB >> 15816547

Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.

Stefan Krüger1, Irina Lange, Ingo Kausch, Alfred C Feller.   

Abstract

BACKGROUND: Due to their variable clinical course, there is a need for new prognostic parameters in minimally invasive (stage T1) bladder carcinomas.
MATERIALS AND METHODS: Using multitissue arrays, protein expression and gene copy numbers of topoisomerase (TOP2alpha), HER2 and p53 were investigated by immunohistochemistry and by fluorescence in situ hybridization (FISH) in 73 T1 tumors. The results were compared with tumor recurrence and progression.
RESULTS: The median TOP2alpha and p53 index was 21% (range, 3-59%) and 7% (range, 0-93%), respectively. HER2 overexpression (score 3+) was detected in 9 cases (12%). High TOP2alpha and p53 indices and HER2 overexpression were significantly associated with earlier tumor recurrence, but not with earlier tumor progression. While TOP2alpha and p53 gene amplification was detected in no case, 5 cases (8%) showed HER2 gene amplification, which was related to HER2 3+ score in 4 cases. Loss of TOP2alpha, HER2 and p53 gene was observed in 4 (8%), 8 (13%) and 6 cases (12%), respectively. By univariate analysis, TOP2alpha index (p=0.0267), HER2 score (p =0.028) and p53 index (p=0.0188) were significantly and loss of TOP2alpha gene (p=0.0575) tendentially correlated with tumor recurrence, while loss of HER2 gene (p=0.069) and loss of p53 gene (p=0.0587) were tendentially correlated with tumor progression. In a multivariate analysis, which also included tumor grade and T1 substage, TOP2alpha index (p=0.043) and p53 index (p=0.02) were identified as independent predictors of tumor recurrence and loss of p53 gene (p=0.012) and T1 substage (p=0.029) as independent predictors of tumor progression.
CONCLUSION: Immuno-histochemical TOP2alpha and p53 staining as well as FISH analysis of p53 gene copy numbers and T1 substaging are helpful means of providing additional information on the biological behavior of T1 transitional cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816547

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups.

Authors:  Weihong Ding; Shijun Tong; Yuancheng Gou; Chuanyu Sun; Hong Wang; Zhongqing Chen; Jun Tan; Ke Xu; Guowei Xia; Qiang Ding
Journal:  World J Urol       Date:  2015-04-18       Impact factor: 4.226

Review 2.  Growth factors and receptors as prognostic markers in urothelial carcinoma.

Authors:  Peter C Black; Colin P N Dinney
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

Review 3.  Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example.

Authors:  Peggy Sekula; Julia B Pressler; Willi Sauerbrei; Peter J Goebell; Bernd J Schmitz-Dräger
Journal:  BMJ Open       Date:  2016-08-16       Impact factor: 2.692

4.  Screening key genes and signaling pathways in colorectal cancer by integrated bioinformatics analysis.

Authors:  Chang Yu; Fuqiang Chen; Jianjun Jiang; Hong Zhang; Meijuan Zhou
Journal:  Mol Med Rep       Date:  2019-06-04       Impact factor: 2.952

5.  HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy.

Authors:  Georgios Moustakas; Spyridon Kampantais; Anastasia Nikolaidou; Ioannis Vakalopoulos; Valentini Tzioufa; Georgios Dimitriadis
Journal:  J Int Med Res       Date:  2020-01       Impact factor: 1.671

6.  Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy.

Authors:  Vinita Agrawal; Niharika Bharti; Rakesh Pandey
Journal:  Arab J Urol       Date:  2020-09-02

7.  Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.

Authors:  G Ferrandina; M Petrillo; A Carbone; G Zannoni; E Martinelli; M Prisco; S Pignata; E Breda; A Savarese; G Scambia
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.